Citadel Advisors
BXRX

Citadel Advisors’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

Citadel Advisors’s Portfolio BXRX Stock Details BXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-27
Closed -$104K – 11767
2020
Q3 		$104K Buy
27
+19
+238% +$86K ﹤0.01% 9257
2020
Q2 		$48K Buy
+8
New +$38.4K ﹤0.01% 9322

Other funds holding BXRX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AWA
Amplius Wealth Advisors Blue Bell, Pennsylvania $1.36B AUM 18.99% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors's BXRX Position: Q4 2021 in Review

Citadel Advisors sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q4 2021, closing a stake of 115 shares — an estimated $90K sold.

Citadel Advisors first reported a position in BXRX in Q4 2019 and held it in 6 quarters. The position peaked at $198K in Q4 2019. 28 funds tracked by Wall St. Rank hold BXRX as of Q4 2021.

  • Citadel Advisors reported no remaining Baudax Bio, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Citadel Advisors sold 115 Baudax Bio, Inc. Common Stock shares in Q4 2021, an estimated $90K.
  • Citadel Advisors first reported a position in Baudax Bio, Inc. Common Stock in Q4 2019 and held it in 6 quarters.
  • Citadel Advisors's Baudax Bio, Inc. Common Stock position peaked at $198K in Q4 2019.
  • 28 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q4 2021.

Based on Citadel Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.